prescribe Dexcom G7: the most accurate CGM system1 for confident diabetes management
From the #1 recommended continuous glucose monitoring brand2,3
new! expanded Medicare coverage
Due to recent Medicare changes, millions more people are now covered for Dexcom CGM. Dexcom G7 is the smallest, most accurate CGM system1 covered by Medicare†—and it’s easy to use and get started!4
No other CGM system is less expensive than Dexcom G7 for Medicare patients.‡
the most accurate CGM system1
For reliable treatment decisions that lead to proven results5-9
Industry-leading MARD (in adults):
8.2% for Dexcom G79 vs. 8.9% for Freestyle Libre 310
MARD (mean absolute relative difference) is a statistical measure of CGM accuracy; the lower the number the better.
Clinically proven to5-9,11:
Clinically proven to5-9,11:
-
Lower A1C
-
Increase time in range
-
Reduce hyper- and hypoglycemia
-
Improve quality of life
Smart device sold separately.*
the simple CGM system
For effortless diabetes management that leads to better adherence§,1
2x faster warmup than FreeStyle Libre4,10 for easy setup and a quick start for you and your patients*
Simple all-in-one wearable for easy application4
60% smaller|| for comfortable, discreet wear
the most covered CGM brand12
For affordable care without compromising quality for the broadest audience of people with diabetes
One-third of patients with commercial insurance have a $0 copay¶,12
Dexcom has 3x more patients paying $0 compared to FreeStyle Libre.#,13
our CGM portfolio can help patients with all types of diabetes gain greater glucose control5-9
The Dexcom CGM Portfolio is an expanding line of CGM systems that support a broad range of people with diabetes. Now you can simply prescribe the powerful CGM system that works best for your patients’ individual needs.
Dexcom G7
the most accurate CGM system1
An intuitive user experience with the advanced accuracy that only Dexcom offers
Dexcom G6
the most connected CGM system1
Industry-leading connectivity with pumps and pens for powerful integrated diabetes control
Dexcom G6 integrates with 60+ connected partners for seamless diabetes management
As the first Class II integrated CGM (iCGM) system authorized by the FDA, Dexcom works with a range of connected insulin pens and automated insulin delivery (AID) system partners. We continue to pursue collaboration opportunities with product and digital health brands, offering a multifaceted approach to effective diabetes management for patients, caregivers, and healthcare providers.
clinical resources to support you
DIaMonD Study1 shows that Dexcom CGM use improves glucose control in adults with type 1 diabetes using insulin injections.
This resource is a brief, illustrated slide deck on setting up and using the Dexcom G7 Continuous Glucose Monitoring (CGM) System with the G7 App and the user’s personal compatible mobile device. The...
*For Medicare coverage of Continuous Glucose Monitoring (CGM), CMS requires use of a receiver. A patient may use a compatible smart device in conjunction with a receiver. †Medicare covers Dexcom CGM for patients who meet the Medicare coverage criteria. For a list of Medicare coverage criteria, please visit the Center for Medicare and Medicaid services website. ‡Under Medicare’s DME fee schedule, reimbursement and coinsurance for CGMs using CPT codes A4239 and E2103 are the same, regardless of CGM brand. §Based on use out of 30 days. ||Compared to a prior generation Dexcom CGM System. ¶Refers to estimated out-of-pocket cost for eligible commercially insured patients from the Dexcom CGM System sensor when claims are adjudicated as a pharmacy benefit, and includes benefits and offerings through available Dexcom programs, such as the voucher program. Actual cost may vary and is subject to individual insurance coverage. #For those with commercial pharmacy coverage. Individual costs may vary and is subject to individual insurance coverage.
1 Dexcom, data on file, 2022. 2 dQ&A US Q1 2021 Diabetes Connections Patient Panel Report. 2021;69-72. 3 Seagrove HCP Survey Q1 2021. 4 Dexcom G7 CGM System User Guide. 5 Beck RW, et al. JAMA. 2017;317(4):371-378. 6 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374. 7 Martens T, et al. JAMA. 2021;325(22):2262-2272. 8 Laffel LM, et al. JAMA. 2020;323(23):2388-2396. 9 Welsh JB, et al. J Diabetes Sci Technol. 2022:19322968221099879. 10 FreeStyle Libre 3 Quick Start Guide. Abbott Diabetes Care Inc.; 2022. 11 Gilbert TR, et al. Diabetes Technol Ther. 2021;23(S1):S35-S39. 12 Managed Markets Insights & Technology, LLC. MMIT Analytics, June 2022. 13 IQVIA February 2022.